Vanguard Global Advisers
CRL icon

Vanguard Global Advisers’s Charles River Laboratories CRL Stock Holding History

Vanguard Global Advisers’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Sell
99,005
-4,491
-4% -$800K 0.01% 553
2026
Q1 		$17.9M Buy
+103,496
New +$19.2M 0.01% 568

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Global Advisers's CRL Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Charles River Laboratories (CRL) stake by 4.3% in Q2 2026, selling an estimated $800K and leaving 99,005 shares worth $22.5M. The position accounts for 0.01% of the portfolio, ranked #553.

Vanguard Global Advisers first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 531 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Vanguard Global Advisers held 99,005 shares of Charles River Laboratories worth $22.5M as of Q2 2026.
  • Vanguard Global Advisers sold 4,491 Charles River Laboratories shares in Q2 2026, an estimated $800K.
  • Charles River Laboratories made up 0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #553 holding.
  • Vanguard Global Advisers first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
  • 531 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.